Clinical trial
Randomized Double Blind Phase 3 Study to Assess the Efficacy and Safety of BoNT/A-DP in the Treatment of Glabellar Lines in Comparison With Placebo Followed by an Open Label Extension Study
NCT02677805 is registered in ClinicalTrials.gov with Croma-Pharma GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Double Blind Phase 3 Study to Assess the Efficacy and Safety of BoNT/A-DP in the Treatment of Glabellar Lines in Comparison With Placebo Followed by an Open Label Extension Study
- Lead sponsor
- Croma-Pharma GmbH
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 30, 2016
- Completion date
- November 3, 2017
- Enrollment
- 251 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
glabellar frown lines